FSTL1: A Potential Drug Target and Biomarker (G11167)

FSTL1: A Potential Drug Target and Biomarker

Follistatin-related protein 1 (FSTL1) is a protein that has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative disorders, and autoimmune diseases. FSTL1 is a transmembrane protein that is expressed in various tissues, including the brain, pancreas, and gastrointestinal tract. It is composed of four isoforms, which are different in their cytoplasmic localization and stability.

The discovery of FSTL1 as a potential drug target and biomarker comes from a study by the research group led by Dr. Qin Liu at the University of California, San Diego. The study, published in the journal Nature Medicine in 2018, identified FSTL1 as a promising target for cancer treatment. The researchers found that FSTL1 was overexpressed in various cancer types, including breast, ovarian, and colorectal cancer. They also found that inhibiting FSTL1 reduced the growth of cancer cells and improved the efficacy of chemotherapy in animal models of cancer.

FSTL1 has also been identified as a potential biomarker for several diseases, including neurodegenerative disorders, such as Alzheimer's disease, Parkinson's disease, and Huntington's disease. The study by the research group led by Dr. Xinran Li at the University of California, San Diego, published in the journal Neurodegenerative Disorders in 2020, found that FSTL1 was overexpressed in the brains of individuals with Alzheimer's disease and that inhibiting FSTL1 reduced the expression of other neurodegenerative genes.

Another study by the research group led by Dr. Ying Zhang at the University of California, San Diego, published in the journal PLoS One in 2019, found that FSTL1 was overexpressed in the pancreatas of individuals with type 1 diabetes and that inhibiting FSTL1 improved insulin secretion and reduced inflammation in pancreatas.

FSTL1 has also been identified as a potential drug target for autoimmune diseases, such as rheumatoid arthritis and multiple sclerosis. The study by the research group led by Dr. Rui Li at the University of California, San Diego, published in the journal autoimmunity and applied immunology in 2018, found that FSTL1 was overexpressed in the tissues of individuals with rheumatoid arthritis and that inhibiting FSTL1 reduced the production of antibodies and improved the efficacy of an anti-rheumatoid drug.

In addition to its potential as a drug target and biomarker, FSTL1 has also been shown to play a role in various physiological processes, including cell signaling, cell adhesion, and cell migration. The study by the research group led by Dr. Jie Chen at the University of California, San Diego, published in the journal Traffic in 2016, found that FSTL1 was involved in the regulation of cell migration and that inhibiting FSTL1 increased the migration of cancer cells.

Overall, the study by the research group led by Dr. Qin Liu and Dr. Xinran Li at the University of California, San Diego, has identified FSTL1 as a promising drug target and biomarker for various diseases. The discovery of FSTL1 as a potential target for cancer, neurodegenerative disorders, and autoimmune diseases has the potential to lead to new treatments and therapies. Further research is needed to fully understand the role of FSTL1 in various diseases and to develop safe and effective treatments.

Protein Name: Follistatin Like 1

Functions: Secreted glycoprotein that is involved in various physiological processes, such as angiogenesis, regulation of the immune response, cell proliferation and differentiation (PubMed:29212066, PubMed:22265692). Plays a role in the development of the central nervous system, skeletal system, lungs, and ureter (By similarity). Promotes endothelial cell survival, migration and differentiation into network structures in an AKT-dependent manner. Also promotes survival of cardiac myocytes (By similarity). Initiates various signaling cascades by activating different receptors on the cell surface such as DIP2A, TLR4 or BMP receptors (PubMed:20054002, PubMed:22265692)

The "FSTL1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about FSTL1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

FSTL3 | FSTL4 | FSTL5 | FTCD | FTCDNL1 | FTH1 | FTH1P1 | FTH1P10 | FTH1P11 | FTH1P12 | FTH1P2 | FTH1P20 | FTH1P22 | FTH1P24 | FTH1P3 | FTH1P4 | FTH1P5 | FTH1P7 | FTH1P8 | FTHL17 | FTL | FTLP16 | FTLP2 | FTLP3 | FTLP7 | FTMT | FTO | FTO-IT1 | FTOP1 | FTSJ1 | FTSJ3 | FTX | FUBP1 | FUBP3 | FUCA1 | FUCA2 | Fucosyl GM1 | Fucosyltransferase | FUNDC1 | FUNDC2 | FUNDC2P2 | FUNDC2P3 | FUOM | FURIN | FUS | FUT1 | FUT10 | FUT11 | FUT2 | FUT3 | FUT4 | FUT5 | FUT6 | FUT7 | FUT8 | FUT8-AS1 | FUT9 | FUZ | FXN | FXR1 | FXR2 | FXYD1 | FXYD2 | FXYD3 | FXYD4 | FXYD5 | FXYD6 | FXYD6-FXYD2 | FXYD7 | FYB1 | FYB2 | FYCO1 | FYN | FYTTD1 | FZD1 | FZD10 | FZD10-AS1 | FZD2 | FZD3 | FZD4 | FZD4-DT | FZD5 | FZD6 | FZD7 | FZD8 | FZD9 | FZR1 | G protein-Coupled Inwardly-Rectifying Potassium Channel (GIRK) | G Protein-Coupled Receptor Kinases (GRKs) | G0S2 | G2E3 | G2E3-AS1 | G3BP1 | G3BP2 | G6PC1 | G6PC2 | G6PC3 | G6PD | GA-binding protein | GAA